| scholarly article | Q13442814 |
| P50 | author | William Pao | Q28025149 |
| Elisa de Stanchina | Q40182100 | ||
| Katerina Politi | Q66809333 | ||
| Valentina Pirazzoli | Q66809411 | ||
| Scott Gettinger | Q66809423 | ||
| Zhongming Zhao | Q85219269 | ||
| Peilin Jia | Q96302804 | ||
| Anna Wurtz | Q111988799 | ||
| Caroline A Nebhan | Q114291498 | ||
| P2093 | author name string | Xiaoling Song | |
| Guoping Cai | |||
| Philip J Stephens | |||
| Molly Gale | |||
| David P Carbone | |||
| Zenta Walther | |||
| Leora Horn | |||
| Erik M Shapiro | |||
| Vincent Miller | |||
| Ruonan Yin | |||
| P2860 | cites work | BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models | Q24649935 |
| Development of new mouse lung tumor models expressing EGFR T790M mutants associated with clinical resistance to kinase inhibitors | Q27302811 | ||
| Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC. | Q27852553 | ||
| A deletion causing NF2 exon 9 skipping is associated with familial autosomal dominant intramedullary ependymoma. | Q30422020 | ||
| Loss of the tumor suppressor gene NF2, encoding merlin, constitutively activates integrin-dependent mTORC1 signaling | Q30437229 | ||
| Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer | Q34773458 | ||
| mTOR kinase inhibition causes feedback-dependent biphasic regulation of AKT signaling | Q35581650 | ||
| mTOR Signaling | Q35762823 | ||
| Contact-dependent inhibition of EGFR signaling by Nf2/Merlin | Q36118464 | ||
| Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling | Q36406541 | ||
| Epidermal growth factor receptor tyrosine kinase inhibitor-resistant disease | Q36660669 | ||
| NF2/merlin is a novel negative regulator of mTOR complex 1, and activation of mTORC1 is associated with meningioma and schwannoma growth | Q37275182 | ||
| Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer | Q37363050 | ||
| Emergence of constitutively active estrogen receptor-α mutations in pretreated advanced estrogen receptor-positive breast cancer | Q37721802 | ||
| Bronchial and peripheral murine lung carcinomas induced by T790M-L858R mutant EGFR respond to HKI-272 and rapamycin combination therapy | Q40110906 | ||
| Erlotinib resistance in mouse models of epidermal growth factor receptor-induced lung adenocarcinoma | Q42017054 | ||
| Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing | Q47163678 | ||
| Molecular genetic alterations on chromosomes 11 and 22 in ependymomas | Q48935245 | ||
| Conditional expression of fibroblast growth factor-7 in the developing and mature lung. | Q52169169 | ||
| P433 | issue | 4 | |
| P921 | main subject | adenocarcinoma | Q356033 |
| cetuximab | Q420296 | ||
| P304 | page(s) | 999-1008 | |
| P577 | publication date | 2014-05-09 | |
| P1433 | published in | Cell Reports | Q5058165 |
| P1476 | title | Acquired resistance of EGFR-mutant lung adenocarcinomas to afatinib plus cetuximab is associated with activation of mTORC1. | |
| P478 | volume | 7 |
| Q37187713 | A HER 1-2 punch: dual EGFR targeting deals resistance a deadly blow |
| Q38717620 | A genetic interaction analysis identifies cancer drivers that modify EGFR dependency |
| Q37301776 | Acquired resistance to combination treatment through loss of synergy with MEK and PI3K inhibitors in colorectal cancer |
| Q36471537 | Afatinib plus Cetuximab Delays Resistance Compared to Single-Agent Erlotinib or Afatinib in Mouse Models of TKI-Naïve EGFR L858R-Induced Lung Adenocarcinoma |
| Q38646686 | Afatinib-based combination regimens for the treatment of solid tumors: rationale, emerging strategies and recent progress |
| Q48165470 | An oligoclonal antibody durably overcomes resistance of lung cancer to third-generation EGFR inhibitors |
| Q39324185 | CRISPR/Cas9-mediated correction of human genetic disease. |
| Q36775204 | Combined EGFR/MEK Inhibition Prevents the Emergence of Resistance in EGFR-Mutant Lung Cancer |
| Q53316010 | Combined Inhibition of NEDD8-Activating Enzyme and mTOR Suppresses NF2 Loss-Driven Tumorigenesis. |
| Q38868047 | Combining three antibodies nullifies feedback-mediated resistance to erlotinib in lung cancer |
| Q58570118 | Comparative mRNA and miRNA transcriptome analysis of a mouse model of IGFIR-driven lung cancer |
| Q37017049 | Comprehensive Genomic Profiling Identifies a Subset of Crizotinib-Responsive ALK-Rearranged Non-Small Cell Lung Cancer Not Detected by Fluorescence In Situ Hybridization |
| Q50920187 | Cytosolic PKM2 stabilizes mutant EGFR protein expression through regulating HSP90-EGFR association. |
| Q35619241 | EGFR: The Paradigm of an Oncogene-Driven Lung Cancer |
| Q38805633 | EPHA2 Blockade Overcomes Acquired Resistance to EGFR Kinase Inhibitors in Lung Cancer |
| Q38964435 | Emerging role of mTOR in the response to cancer therapeutics |
| Q35152542 | Erlotinib-cisplatin combination inhibits growth and angiogenesis through c-MYC and HIF-1α in EGFR-mutated lung cancer in vitro and in vivo |
| Q42183080 | In vivo engineering of oncogenic chromosomal rearrangements with the CRISPR/Cas9 system. |
| Q47098234 | Increased EGFR Phosphorylation Correlates with Higher Programmed Death Ligand-1 Expression: Analysis of TKI-Resistant Lung Cancer Cell Lines |
| Q27316840 | NHERF1/EBP50 and NF2 as diagnostic markers for choroid plexus tumors |
| Q36375590 | Network based stratification of major cancers by integrating somatic mutation and gene expression data. |
| Q35671019 | Network-based stratification analysis of 13 major cancer types using mutations in panels of cancer genes |
| Q38990576 | Novel EGFR Inhibitors in Non-small Cell Lung Cancer: Current Status of Afatinib. |
| Q35112467 | Optimizing the sequence of anti-EGFR-targeted therapy in EGFR-mutant lung cancer |
| Q38629644 | PTEN and PI3K/AKT in non-small-cell lung cancer. |
| Q93000736 | Paired Box-1 (PAX1) Activates Multiple Phosphatases and Inhibits Kinase Cascades in Cervical Cancer |
| Q35819517 | Personalized targeted therapy for esophageal squamous cell carcinoma |
| Q38745430 | Primary Double-Strike Therapy for Cancers to Overcome EGFR Kinase Inhibitor Resistance: Proposal from the Bench |
| Q55195646 | Resistant to Targeted Therapy - Aim for Metabolic Liabilities. |
| Q33881153 | Retinoic Acid affects Lung Adenocarcinoma growth by inducing differentiation via GATA6 activation and EGFR and Wnt inhibition |
| Q38746756 | Therapy-induced E-cadherin downregulation alters expression of programmed death ligand-1 in lung cancer cells |
| Q33787355 | Triplet therapy with afatinib, cetuximab, and bevacizumab induces deep remission in lung cancer cells harboring EGFR T790M in vivo |
| Q60395350 | mTOR mediates a mechanism of resistance to chemotherapy and defines a rational combination strategy to treat KRAS-mutant lung cancer |
| Q99564796 | mTOR-mediated cancer drug resistance suppresses autophagy and generates a druggable metabolic vulnerability |
Search more.